Bladder squamous cell carcinoma

Summary

Bladder squamous cell carcinoma (MONDO:0002760) is a cancer and 14 clinical trials. Top therapeutic interventions include cabozantinib, enfortumab vedotin, and sacituzumab govitecan. A subtype of urinary bladder carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 14

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	bladder squamous cell carcinoma
Mondo ID	MONDO:0002760
EFO	EFO:1000130
DOID	DOID:3742
NCIT	C4031
SNOMED CT	255111004
UMLS	C0279681
MedGen	124645
Anatomy (UBERON)	UBERON:0001255
Is cancer (heuristic)	yes

Also known as: bladder epidermoid carcinoma · bladder squamous cell cancer · bladder squamous cell carcinoma · BLSC · epidermoid carcinoma of bladder · epidermoid carcinoma of the bladder · epidermoid carcinoma of the urinary bladder · epidermoid carcinoma of urinary bladder · squamous cell carcinoma of bladder · squamous cell carcinoma of the bladder · squamous cell carcinoma of the urinary bladder · squamous cell carcinoma of urinary bladder · urinary bladder epidermoid carcinoma · urinary bladder squamous cell carcinoma

Data availability: 3 cell lines.

Disease family

This is a subtype of urinary bladder carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › urinary bladder disorder › urinary bladder neoplasm › urinary bladder cancer › urinary bladder carcinoma › bladder squamous cell carcinoma

Related subtypes (8): bladder adenocarcinoma, bladder urachal carcinoma, urinary bladder small cell neuroendocrine carcinoma, stage IVb bladder cancer, superficial urinary bladder carcinoma, bladder transitional cell carcinoma, childhood bladder carcinoma, bladder small cell carcinoma

Subtypes (2): bladder verrucous carcinoma, bladder urachal squamous cell carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 14.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	10
PHASE1	2
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03866382	PHASE2	RECRUITING	Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
NCT05756569	PHASE2	RECRUITING	Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
NCT06041503	PHASE2	RECRUITING	Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)
NCT06161532	PHASE2	RECRUITING	Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C…
NCT00005831	PHASE2	COMPLETED	Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer
NCT00112905	PHASE2	TERMINATED	Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium
NCT00407485	PHASE2	COMPLETED	VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium
NCT01611662	PHASE2	TERMINATED	Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer
NCT03430895	PHASE2	COMPLETED	Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract
NCT03912818	PHASE2	TERMINATED	Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer
NCT02496208	PHASE1	ACTIVE_NOT_RECRUITING	Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
NCT00072137	PHASE1	TERMINATED	Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy
NCT01954173	Not specified	TERMINATED	Adjuvant Radiation for High Risk Bladder Cancer
NCT04815629	Not specified	UNKNOWN	Outcome of Radiation Therapy in Urinary Bladder Squampus Cell Carcinoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CABOZANTINIB	4	4
ENFORTUMAB VEDOTIN	4	2
SACITUZUMAB GOVITECAN	4	1
SORAFENIB	4	1
TRASTUZUMAB	4	1
TREMELIMUMAB	4	1
VINBLASTINE	4	1
CHEMBL4788494	0	1